cyrilzakka/clinical-trials huggingface dataset:
Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant

The purpose of this study is to determine whether vitamin D is effective in the prevention of graft-versus-host-disease after completion of allogeneic transplant.

The allogeneic transplant of haematopoietic cell is the only treatment option for many malignant blood diseases. Unfortunately, the progression free survival and the quality of life of transplanted patients is limited due to the development of graft-versus-host-disease (GVHD).

The development of new prophylaxis strategies of GVHD based in the use of immunomodulator agents (allowing the generation of an immunotolerance state and avoiding the use of immunosuppression) is essential.

The GVHD is due to the cytotoxic effect of the donor lymphocytes T against healthy organs and tissues of the receptor. Calcineurin inhibitor combined with methotrexate or antibodies anti-lymphocytes T are used as standard prophylaxis. This type of antibodies has demonstrated efficacy to reduce GVHD, but have not increased survival due to increasing the risk of relapses and serious post-transplant infections.

Due to its interactions with VDR (vitamin D receptor) present in immune system cells, vitamin D is able to inhibit the activation of dendritic cells and the proliferation and production of cytokines by lymphocytes T. Based on this effect, the peri- and post- transplant administration of vitamin D might decrease the risk of GVHD in allogeneic transplanted patients, subsequently decreasing the immunosuppressant treatment requirements and improving the prognosis of those patients.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* The patient should accomplish all the criteria to proceed to an allogeneic transplant
* The patient or their legal guardians should signed the informed consent approved by the Ethics Committees of Clinical Trials

Exclusion Criteria:

* Hypercalcemia ≥ 10.5 mg/dl
* Renal insufficiency with creatinine level ≥ 2 x upper limit of normal (1,1 mg/dl)
* Participation in others Clinical Trials in which the intervention may affect the result of the study.
* Patients receiving GVHD immunoprophylaxis with thymoglobuline or GVHD prophylaxis including in vitro or in vivo lymphocytes T depletion (anti-lymphocyte T globulin, ALG)
* Patients receiving a transplant from an haploidentical donor
Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

In this study, effects of γδT cells on human non small lung cancer ( without EGFR mutation) in combination with tumor reducing surgery, for example cryosurgery going to be investigated.

Non small lung cancer will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell and DC-CIK, they will be infused to the patients as immunotherapy.

Eligibility Criteria:
Inclusion Criteria:

1. Age:18-75
2. Karnofsky performance status \>50
3. Diagnosis with non small lung tumors based on histology or the current accepted radiological measures.
4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, gd Tcells/ DC-CIK.
5. Life expectancy: Greater than 3 months
6. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion Criteria:

1. Patients with other kinds of cancer
2. History of coagulation disorders or anemia
3. Patients with heart disease and diabetes
Assessing a New Tool to Assess Frailty in Frail Hospitalized Elderly

The major purpose of this study is to establish the use of daily step counts as inexpensive, easy to measure marker for frailty and sarcopenia in an inpatient population of older adults.

The total time involved to complete study procedures will be between 2-3 hours at your enrollment and up to 10 minutes at your discharge. Investigators will invite participants to enrol in this study at your admission and discharge days.

Firstly, Investigators would like to collect some demographic data, including participants age and gender.

Then Investigators will ask participants to check their blood pressure and heart rate, weight, height and Body Mass Index.

Also Investigators will collect participant's medication List and Past Medical History.

Then, Investigators would like to ask participants to carry special device on their mid-thigh. It's called 'ActivPAL' and a trained research assistant will fit it on participant's dominant leg. This device has ability to detect the joint angle of participant's thigh to capture lying, sitting, standing, and stepping activities.

Then Investigators will proceed to ultrasound test. Participants will be asked to lay down on the bed with their legs supported by a pillow. Then a study physician will use ultrasound to measure participant's leg muscles. Three measurements will be taken for each participant.

After that participant will be asked to do a "Grip test". Participant will be asked to squeeze special device, called dynamometer, using your dominant hand. Each participant will be asked to make three attempts with half a minute break between each measurement.

Participant will be asked to walk 10-15 meters in order to measure their gait speed.

Impedance measures of body composition will be performed using an automatic scale.

At the end Investigators will ask you to measure participant's body structure, using skinfold/caliper device.

At participant discharge Investigators will remove 'ActivPal' sensor from their leg that was fitted at enrollment.

Eligibility Criteria:
Inclusion Criteria:

* be 65 years of age or older
* be admitted in ACE Unit

Exclusion Criteria:

* be less than 65 years of age
* be nonambulatory
* be diagnosed with end-stage organ failure (end-stage COPD, renal failure requiring dialysis, end-stage heart failure)
Online Survey: Oncologists' Thoughts Regarding Their Patients

Our study is a questionnaire targeting the medical staff in Oncology. It aims at exploring the thoughts and expectations of the medical staff in Oncology regarding their patients management and prognosis worldwide. It also investigates the factors that affect these thoughts and expectations and their effects.

Oncology patients need to trust the medical staff dealing with them. They are expecting knowledge, well communication, competence .. etc. This Questionnaire is for research purpose aiming at exploring the thoughts and expectations of the medical staff in Oncology regarding their patients management and prognosis worldwide. It investigates the factors that affect these thoughts and expectations and their effects. The results of this survey will shed the light on the oncologists' side of their relationship with their patients, which is often ignored or down played.

Eligibility Criteria:
Inclusion Criteria:

1. Medical/Clinical/Radiation Oncology Physicians
2. Surgical Oncology Physicians
3. Oncology nurses

Exclusion Criteria:

* Medical staff not related to oncology field
A Randomized Study Comparing of Three Doses Nebulized Fentanyl in Older Adults

This clinical trial compares three different nebulized fentanyl dosages for older persons experiencing severe musculoskeletal pain at the emergency department.

The main objective is:

Does the effectiveness of nebulized fentanyl at dosages of 2 mcg/kg, 3 mcg/kg, and 4 mcg/kg at 30 minutes differ in older patients who report to the emergency room with pain from musculoskeletal injuries?

Secondary outcome are:

1. Incidence of adverse effects after drug administration at minutes 0, 15, 30, 45, 60, 75, 90, 105, 120
2. Incidence of receiving other pain relief treatments (rescue therapy) in minutes 30, 45, 60, 75, 90, 105, 120 Participants will receive an explanation of the study and possible side effects, which may take approximately 5-10 minutes, without affecting the primary treatment of the patients. Consent will be obtained in this study, along with signing or fingerprinting as evidence in the consent form.

Participants will receive nebulized fentanyl for pain reduction at the pre-determined randomized dose, then researchers will follow up assessments of pain levels, vital signs, and any side effects at various intervals.

Eligibility Criteria:
Inclusion Criteria:

* Age more than or equal 65 years old.
* Presented with musculoskeletal pain within 3 days.
* Pain score on verbal numeric rating scale ≥ 5.

Exclusion Criteria:

* Patients need immediate intervention.
* Patients need acute rescue for acute coronary syndrome, respiratory failure, and stroke.
* Creatinine clearance \< 30 ml/min, Cirrhosis stage III, IV (present with ascites and varices).
* Trauma \>2 organ.
* Comorbidities of chronic obstructive pulmonary disease.
* Take MAO inhibitors within 14 days.
* History of opioid used within 8 hours.
* History of alcohol or drug abuse.
* History of fentanyl allergy.
* Patients with difficulty to communication (e.g. altered mental status, severe dementia (define by 6-items cognitive screening \> 12, language barrier).
Exposure-based Treatment for Avoidant Back Pain Patients

Chronic low back pain often results in psychosocial and physical disability. A subgroup of these patients shows fear of (re)injury and avoidance behaviour leading to higher disability. The purpose of this study is to determine whether exposure in vivo is more effective in the treatment of fear avoidant chronic back pain patients than psychological treatment as usual (cognitive behavioural psychotherapy).


Eligibility Criteria:
Inclusion Criteria:

* Having at least 3 months back pain
* Sufficient level on fear avoidance scores (TSK, Phoda)
* Being German-speaking
* Agreeing to participate, verified by completion of informed consent

Exclusion Criteria:

* Red flags
* Pregnancy
* Illiteracy
* Psychoses
* Alcohol addiction
* surgeries during the last 6 months or planed surgeries
* Specific medical disorders or cardiovascular diseases preventing participation in physical exercise
* Participating in another psychotherapy
Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in 48\~72 hours.

Eligibility Criteria:
Inclusion Criteria:

* Healthy adults aged 19-64 years old
* Informed consent form has been signed and dated
* Able to comply with the requirements of the study
* Female subjects who have negative results in Urine hCG test at screening, or menopausal women.

Exclusion Criteria:

* Subjects who have positive results(;induration diameter over 5mm) in Tuberculin Skin Test(TST) at screening
* Subjects who shown abnormal results(including inactive tuberculosis) on Chest X-ray at screening
* Subjects who received a vaccination(including live vaccine) within 28 days before enrollment
* Subjects who are on antituberculosis drugs
* Immunocompromised subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy
* Subjects with severe chronic disease who are considered by investigator to be ineligible for the study
* Pregant or lactating women
Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Although we know that these numbers are underestimated, Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory disease that affects between 8 and 12% of adults. According to a 2020 WHO report, it is the third most common cause of mortality in developed countries. This disease is punctuated by exacerbations associated with an 8% mortality of hospitalized patients, increased to 24% when the patient is admitted to intensive care unit. Early detection and treatment of these exacerbations appears to be essential to improve patient survival. End-tidal carbon dioxide (EtCO2) is used to assess a patient's respiratory and hemodynamic status. Indeed, EtCO2 is a non-invasive measure that could allow the estimation of arterial carbon dioxide (PaCO2) without performing blood gases, an arterial blood sampling, classically at the radial artery. This study aimed to find an EtCO2 value which at the time of the initial management, would be predictive of a severe COPD exacerbation, as well as PaCO2.

The study will be conducted in the emergency departments of Grenoble and Lyon University Hospitals.

Patients will be recruited by the dispatch nurse at the emergency department reception according to the inclusion and non-inclusion criteria. The EtCO2 will be measured at the emergency reception during assessment of vital signs by the same nurse with the help of a mask or oxygen glasses measuring EtCO2. The patient will then be treated conventionally according to current international recommendations. The physician in charge of the patient will be blinded to this measurement. Once the patient is discharged from the emergency department, the primary and secondary endpoints will be collected by a clinical research associate 24 hours after admission from medical record.

Eligibility Criteria:
Inclusion Criteria:

* All patient presenting to the emergency department with acute dyspnea and with a history of COPD documented or reported by the patient and/or family
* Male or female≥18 years old who did not oppose to participating in the study

Exclusion Criteria:

* Hypotension (SBP \< 90 mmHg or MBP \< 65 mmHg)
* Patient already included in the study during a previous visit to the emergency department
* Patient already ventilated with invasive or NIV during admission to the emergency department
* COPD exacerbation rejected after medical and additional examinations
* Non-communicative or non-French speaking patients, or with impaired comprehension, or with impaired consciousness
* Protected persons referred to in articles L1121-6 and L1121-8 of French public health code (deprived of liberty, tutorship or curatorship)
Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI)

A comparative prospective study to evaluate different imaging modalities (pet-ct and pet-mr) prior to surgery in parathyroid tumor patients.

Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. in addition to the conservative 99mTc-MIBI (methoxyisobutylisonitrile) and US, patients will also undergo 18FCH (¹⁸F-choline) PET/MRI for detecting adenomas and their location. imaging experts will decode the imaging exams. sensitivity and specificity of the exams will be examined.

Eligibility Criteria:
Inclusion Criteria:

Patients who meet the criteria accepted in the World Health Organization (WHO) analysis:

* Symptomatic patients (constipation, depression, peptic ulcer, pathologic fractures, chronic fatigue, pain from a urinary tract stones etc..)

or at least one of the following criteria:

* Blood calcium levels above 1 more than normal
* Creatinine clearance decreased in 30% from age expected
* Urine Creatinine above 400 mg in 24 hours

Exclusion Criteria:

* Patients with hyperthyroidism secondary and tertiary (secondary to kidney disease)
* Patients who are not eligible to sign an informed consent
* Pregnant women
* Patients with sensitivity (allergy) technetium or 18FCH
Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females

The purpose of this study is to determine whether the Hair Loss Prevention Lotion named MEXIS, M.P.A.F., M6S PATENT is effective in the treatment of Alopecia Areata.

This study verifies whether the tested product has any efficacy in the treatment of Alopecia Areata.

* The evaluated product (Hair Loss prevention Lotion) is called: MEXIS, MPAF, M6S PATENT.
* 20 volunteers both men and women suffering from hair loss both in parties and over the entire scalp with age between 18 and 70 years will be selected for this test .
* Samples of the product have been applied following their usual use: as they are.
* On the selecting volunteers will be used:

A polarized light video-camera to check the redness of the scalp and to have a picture of hair and scalp.

* Volunteers will also be asked about:
* Fluffiness
* Sheen
* Itching
* Presence of scales on scalp
* Oily hair
* Product's acceptability
* The readings will be taken at 0 time (basal value), after 15 days (t15), 30 days (t30), 45 days (t45), 45 days (t45), 60 days (t60) and 90 days (t90) by the experimenter in the medical studio. Then they analyzed and reported in a graph.
* Summarizing tables and graphs of the data will be taken during experimentation.

Eligibility Criteria:
Inclusion Criteria:

* Good state of general health
* Suffering from Alopecia Areata
* No pharmacological treatment in progress
* Promise not to change the usual daily routine
* No atopy in the anamnesis

Exclusion Criteria:

* Illness
* Good state of hair
* Pharmacological treatment in progress
* Denial of the continuance of the usual daily routine
* Atopy in the anamnesis
Prospective Clinical Evaluation of ASR and ReCap Resurfacing Arthroplasty

This evaluation is being conducted to evaluate the performance of the ASR arthroplasty. The performance of the devices will be assessed by:

Clinical parameters: pain, function, satisfaction and complications. Blood samples: Analyse of metal ions, lymphocyte migration, lymphocyte proliferation assay and cytokines.

Biopsies: Metal ions, cytokines and histology. Biomechanics: Strength, gait analysis, range of motion. Scanning: DEXA and MRI


Eligibility Criteria:
Inclusion Criteria:

ASA I-II,DEXA-scanning:

* lower limit for a 55 years old women,
* MRI normal
* vitality in caput
* willing to return for follow-up evaluations.

Exclusion Criteria:

* collum femoris \< 2 cm
* large cysts in caput (\> 1 cm)
* mismatch between caput and acetabulum
* caput necrosis
* treatment with medicine which affects bone metabolism
* impaired kidney function.
Metaverse-Based Healthy Life Program for Youth

This study was planned within the scope of the call titled "Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases - GACD)" with identity number HORIZON-HLTH-2022-DISEASE-07-03. The purpose of this project; is to determine the effect of the Metaverse-Based Healthy Life Program to be developed in the project to support youths in decreasing future risks of developing non-communicable diseases (NCDs) and in gaining healthy lifestyle behaviors (HLBs).

The project consists of three phases. Phase 1 Testing the content, quality, reliability, and usability of the "Metaverse-Based Healthy Life Program for Youth" to be developed within the scope of the project Phase 2 Identifying youth at high risk of chronic non-communicable diseases in the research population Phase 3 Evaluating the effect of "Metaverse-Based Healthy Life Program for Youth" implementation on inculcating healthy lifestyle behaviors in youth

Eligibility Criteria:
Inclusion Criteria:

* Being a university student in the project partner countries and not older than 24,
* Having a score of 130 or lower on the HLBS II in the first stage of the research,
* Determining that BMI ≥ 25-34.99 kg/m2 in the first stage of the research and
* Using a smartwatch during the research,
* Accepting to participate in the research voluntarily

Exclusion Criteria:

* Having chronic diseases (asthma, diabetes, heart, kidney failure, hypertension, cancer, etc.)
* Those who have a drug that they use constantly
* Having a psychiatric diagnosis (depression, anxiety, bipolar disorder, schizophrenia, etc.)
* Having a disease that prevents the use of metaverse (vertigo, vision, hearing, etc.)
Phototherapy Applied in Association With Strength Training

The effects of phototherapy has been widely studied by some research groups. The investigators know that there are positive results with light application to improve muscle performance and delay fatigue. However, there are few studies showing its´ effects on muscular training. Therefore, the aim of this study was to assess the effects of phototherapy applied at different times during 12 weeks of strength training. For such, 48 volunteers, healthy male, from 18 to 35 years old were recruited to perform a strength training protocol for the anterior muscle of the thigh development. Volunteers performed the training protocol twice a week for 12 weeks. There were assessed isometric peak torque in isokinetic dynamometer, 1-repetition maximum test in the leg extension and leg press machines and bilateral thigh perimetry.

This is a clinical, randomized, controlled placebo and double-blind study. Forty-eight participants performed strength training protocol. Subjects practiced a protocol training with 80% of the load, measured through 1-repetition maximum test. The training protocol consisted in performing 5 sets of 10 repetitions, twice a week, employing leg extension and leg press machines.

Phototherapy, active or placebo, were applied in 6 different points of anterior muscle of the thigh before and after each training session. Only one investigator, that did not participate in any phase of the assessments and trainings sessions, knew about what program is active or placebo in phototherapy device. Randomisation carried out by a simple drawing of lots (A, B, C, or D) in the first visit. The phototherapy unit emitted the same sound regardless of the program used, active or placebo. Either strength training lasted 12 weeks and assessments were performed at baseline, 4, 8 and 12 weeks. There were evaluated maximal voluntary contraction (MVC), bilateral thigh perimetry and 1-repetition maximum test (1-RM).

Eligibility Criteria:
Inclusion Criteria:

There were included in the study

* healthy individuals,
* active,
* aged between 18 and 35 years old,
* male,
* presenting no history of musculoskeletal injury in the regions of the hip and knee in the two months prior to the study.
* that are not making use of pharmacological agents and / or nutritional supplements, and
* that have at least 80% of attendance to training.

Exclusion Criteria:

The participants were excluded if they

* present some musculoskeletal injury during the study